Aligos Therapeutics (ALGS) Current Assets (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Current Assets came in at $59.6 million in Q1 2026, down 58.36% YoY from $143.2 million in Q1 2025, and down 28.04% on a QoQ basis from $82.9 million in Q4 2025.
Aligos Therapeutics (ALGS) Current Assets (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Current Assets data on file, last reported at $59.6 million in Q1 2026.
- Quarterly Current Assets fell 58.36% year-over-year to $59.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.6 million (down 58.36% YoY) and the FY2025 annual result came in at $82.9 million, up 33.35% from the prior year.
- Current Assets eased to $59.6 million in Q1 2026, from $82.9 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $195.1 million in Q1 2022 to a low of $59.6 million in Q1 2026.
- A 5-year average of $114.3 million and a median of $109.4 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2025 — Current Assets jumped 33.35% — and 2026, when it slumped 58.36%.
- Tracing ALGS's Current Assets over 5 years: stood at $133.5 million in 2022, then climbed by 5.65% to $141.1 million in 2023, then slumped by 55.95% to $62.1 million in 2024, then surged by 33.35% to $82.9 million in 2025, then slipped by 28.04% to $59.6 million in 2026.
- The last three Current Assets figures came in at $59.6 million (Q1 2026), $82.9 million (Q4 2025), and $103.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 1.76 Bn |
| 10 | Aligos Therapeutics | 67.75 Mn | 37.31 Mn | - | 62.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.13 Mn |
| Mar 31, 2026 | 59.63 Mn |
| Dec 31, 2025 | 82.86 Mn |
| Sep 30, 2025 | 103.44 Mn |
| Jun 30, 2025 | 127.94 Mn |
| Mar 31, 2025 | 143.21 Mn |
| Dec 31, 2024 | 62.14 Mn |
| Sep 30, 2024 | 79.82 Mn |
| Jun 30, 2024 | 99.57 Mn |
| Mar 31, 2024 | 118.06 Mn |
| Dec 31, 2023 | 141.08 Mn |
| Sep 30, 2023 | 74.64 Mn |
| Jun 30, 2023 | 94.24 Mn |
| Mar 31, 2023 | 109.43 Mn |
| Dec 31, 2022 | 133.55 Mn |
| Sep 30, 2022 | 150.09 Mn |
| Jun 30, 2022 | 167.69 Mn |
| Mar 31, 2022 | 195.08 Mn |
| Dec 31, 2021 | 204.42 Mn |
| Sep 30, 2021 | 248.67 Mn |